The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study to evaluate the effects of docetaxel plus lycopene in advanced castrate-resistant prostate cancer.
 
Eric Zhuang
No Relationships to Disclose
 
Edward M. Uchio
Research Funding - Ambry Genetics; Bayer; Clovis Oncology; GenomeDx; Genomic Health; Janssen Oncology; Merck; Merit Medical Systems; Myovant Sciences; Myovant Sciences; Myriad Genetics; Pfizer
(OPTIONAL) Uncompensated Relationships - Bayer; Genomic Health; Janssen Oncology; Merck; Myriad Genetics; Pfizer
 
Michael B. Lilly
Speakers' Bureau - Guardant Health
Research Funding - Bavarian Nordic (Inst); Bayer (Inst)
 
John P. Fruehauf
Leadership - 300 Cells
Consulting or Advisory Role - Novartis
Speakers' Bureau - Genentech/Roche; Merck; Novartis; Sanofi
Travel, Accommodations, Expenses - Genzyme; Merck Sharp & Dohme; Novartis